Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI

Caroli, Anna; Prestia, Annapaola; Wade, Sara; Chen, Kewei; Ayutyanont, Napatkamon; Landau, Susan M; Madison, Cindee M; Haense, Cathleen; Herholz, Karl; Reiman, Eric M; Jagust, William J; Frisoni, Giovanni

doi:10.1097/WAD.0000000000000071

Scientific article

English

Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI

ContributorsCaroli, Anna; Prestia, Annapaola; Wade, Sara; Chen, Kewei; Ayutyanont, Napatkamon; Landau, Susan M; Madison, Cindee M; Haense, Cathleen; Herholz, Karl; Reiman, Eric M; Jagust, William J; Frisoni, Giovanni

Published inAlzheimer disease and associated disorders

Publication date2014

Abstract

Aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI).

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de psychiatrie

Research groups

Troubles de mémoire et maladie d'Alzeimer (935)

Citation (ISO format)

CAROLI, Anna et al. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. In: Alzheimer disease and associated disorders, 2014. doi: 10.1097/WAD.0000000000000071

Article (Accepted version)

Identifiers

PID : unige:48292
DOI : 10.1097/WAD.0000000000000071
PMID : 25437302

Journal ISSN0893-0341

588views

1downloads

Creation15/12/2014 10:37:00

First validation15/12/2014 10:37:00

Update14/03/2023 23:02:32

Status update14/03/2023 23:02:31

Last indexation30/10/2024 23:33:50

Archive ouverte UNIGE

Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI

Aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI).

Technical informations